Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19

Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcão, Melissa Barreto, Pamplona de Góes Cavalcanti, Luciano, Filgueiras Filho, Nivaldo Menezes, Antunes de Brito, Carlos Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253107/
https://www.ncbi.nlm.nih.gov/pubmed/32314698
http://dx.doi.org/10.4269/ajtmh.20-0276
Descripción
Sumario:Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibited a 10-fold increase in serum levels of transaminases, followed by a rapid decrease after HCQ was withdrawn. Considering the significantly increased use of HCQ during the COVID-19 pandemic, this case alerts us to the potential for HCQ to be associated with hepatotoxicity and the need to monitor liver function during HCQ therapy.

Ejemplares similares